Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 580Neoplasms 487Prostatic Neoplasms 311Lung Neoplasms 238Colorectal Neoplasms 201Motor Activity 131Carcinoma, Non-Small-Cell Lung 117Uterine Cervical Neoplasms 112Brain Neoplasms 110Pancreatic Neoplasms 108Head and Neck Neoplasms 106Stomach Neoplasms 99Carcinoma, Hepatocellular 99Rectal Neoplasms 97Ovarian Neoplasms 86Colonic Neoplasms 86Neoplasm Metastasis 67Multiple Myeloma 65Esophageal Neoplasms 65Hematologic Neoplasms 61Urinary Bladder Neoplasms 60Glioblastoma 59Melanoma 58Sarcoma 57Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Endometrial Neoplasms 56Glioma 53Lymphoma 50Leukemia, Myeloid, Acute 48Gastrointestinal Neoplasms 48

Interventions

exemestane 1Tamoxifen 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Letrozole 1Fulvestrant 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Recruiting × HR Positive HER2 Negative Advanced Breast Cancer × Clear all
NCT05890287 2023-06-06

A Study of Chidamide Plus Endocrine in Maintenance Treatment of HR+/HER2- Breast Cancer After First-line Chemotherapy

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
60 enrolled
Breast

HR Positive HER2 Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡